Algorithm for selection of drug for osteoporosis treatment in primary care and in organization of provision with medicinal products of citizens eligible for state social assistance. Review of the literature and position of Russian Association on Osteoporosis Expert Council

Мазуров, В. И.; Lesnyak, Olga; Belova, K. Yu.; Ершова, О. Б.; Зоткин, Е. Г.; Marchenkova, Larisa; ROZhINSKAYa, L Ya; Скрипникова, И. А.

doi:10.17116/profmed20192201157

Cited by 19 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В рандомизированных плацебо-контролируемых исследованиях показано, что прием 70 мг алендроната один раз в неделю обеспечивает терапевтическую эквивалентность ежедневной дозе препарата 10 мг и одновременно лучшую переносимость, а также удобство применения (уровень доказательности В) [9][10][11][12][13][14]. На материале, полученном при проведении биопсий подвздошной кости, не выявлено признаков остеомаляции.…”

Section: эффективность алендроната в профилактике переломовunclassified

“…В 3-месячном исследовании была оценена безопасность алендроната (70 мг/нед) по сравнению с плацебо у больных, принимающих сопутствующую терапию НПВП. Частота нежелательных явлений со стороны верхних отделов желудочно-кишечного тракта была одинакова в обеих группах (9,3% и 10,8% соответственно, р = 0,744) [14]. Алендронат относительно противопоказан больным с острыми заболеваниями верхних отделов желудочно-кишечного тракта.…”

Section: эффективность алендроната в профилактике переломовunclassified

See 1 more Smart Citation

Use of alendronate in the therapy of osteoporosis

Ершова

2020

Medicinskij sovet

Self Cite

View full text Add to dashboard Cite

Treatment of osteoporosis is a difficult task due to the need for long-term medication and maximum safety. The main goal of osteoporosis treatment is to prevent bone fractures. According to the national clinical guidelines for the treatment of osteoporosis, nitrogen-containing bisphosphonates are among the first-line drugs for the prevention and treatment of this disease. The diversity in the side chain structure determines the strength with which bisphosphonates bind to hydroxyapatite, are distributed, and remain in bone tissue for a certain time after treatment has been completed. They are the drugs of choice as they have proven efficacy in reducing the risk of fractures, and at the same time an acceptable safety profile. Bisphosphonates are the most well-known and studied drugs, successfully used in all countries for the treatment of various forms of osteoporosis. When using oral forms of bisphosphonates, the most expected undesirable phenomenon is esophagitis. The development of new forms of well-known and proven medicines that reduce adverse events and increase adherence to treatment is extremely important and promising. Of the latest achievements in this regard, it should be noted a new form of alendronate-Binosto-effervescent soluble tablet, the use of which reduces the risk of irritating effects on the upper gastrointestinal tract.

show abstract

Section: эффективность алендроната в профилактике переломовunclassified

Use of alendronate in the therapy of osteoporosis

Ершова

2020

Medicinskij sovet

Self Cite

View full text Add to dashboard Cite

show abstract

“…Среди них наиболее востребованными являются лекарственные средства антирезорбтивного действия, в частности бисфосфонаты (алендронат, золедронат, ибандронат, ризедронат) и моноклональные антитела к RANKL (деносумаб), а также анаболического (пептид паратгормона терипаратид и другие) и двойного действия [3]. Препаратами первой линии для лечения женщин с постменопаузальным ОП считаются пероральные бисфосфонаты [4,5]. Основными клетками мишенями для данных препаратов являются остеокласты, а терапевтическое их действие обусловлено свойством подавлять функциональную активность вышеуказанных клеток и тем самым уменьшать резорбцию костной ткани.…”

Section: оригинальные статьиunclassified

“…Согласно современным алгоритмам ведения пациентов с постменопаузальным ОП, в случае отсутствия эффекта от приема таблетированных форм бисфосфонатов рекомендуется замена препаратов и переход на другие схемы терапии [5]. Необходимо отметить, что продолжительность лечения постменопаузального ОП должна быть не менее 3 -5 лет, а в некоторых случаях -10 лет и более.…”

Section: оригинальные статьиunclassified

The influence of individual genetic polymorphisms on postmenopausal osteoporosis treatment effectiveness

Резниченко¹,

Симрок

Adunts³

2020

Med. vestn. Ûga Ross.

View full text Add to dashboard Cite

Objective: study of associations between VDR gene rs1544410 and rs10735810 polymorphisms, MCM6 gene rs4988235, CALCR gene rs1801197 one and ibandronate efficacy in women with postmenopausal osteoporosis.Materials and methods: 117 women with postmenopausal osteoporosis were examined for 12 months in the dynamics of treatment with ibandronate. Evaluation of therapy effectiveness was based on indicators of increase in bone mineral density in L1-L4 lumbar vertebrae, as well as left and right femurs.Results: An association of GG genotype of VDR gene rs1544410 polymorphism with low growth rates of mineral density of L1-L4 lumbar vertebrae (3,41 ± 0,60 % versus 5,51 ± 0,78 % in other women; р = 0,036) was established. The effect of other studied polymorphisms (rs10735810 of VDR gene, rs4988235 of MCM6 gene, rs1801197 of CALCR gene) on treatment effectiveness was not found.Conclusion: it is advisable to use obtained results when developing personalized regimens for antiresorptive therapy for women with postmenopausal osteoporosis.

show abstract

Steroid osteoporosis within the framework of the Itsenko-Cushing drug syndrome: demonstration of a clinical case

Fleyshman

Belyaeva

2021

Clinical Medicine and Pharmacology

View full text Add to dashboard Cite

A case of severe systemic osteoporosis complicated by multiple fractures of the ribs and vertebrae in a young patient with late diagnosis of Still's disease as a result of independent long-term uncontrolled use of corticosteroids is presented. Lack of medical supervision, taking a high dose (35 mg / day) of prednisolone without recommendation and control of treatment led to untimely recognition and treatment of the underlying disease and the development of irreversible disabling transformations of the skeleton.

show abstract

Algorithm for selection of drug for osteoporosis treatment in primary care and in organization of provision with medicinal products of citizens eligible for state social assistance. Review of the literature and position of Russian Association on Osteoporosis Expert Council

Cited by 19 publications

References 32 publications

Use of alendronate in the therapy of osteoporosis

Use of alendronate in the therapy of osteoporosis

The influence of individual genetic polymorphisms on postmenopausal osteoporosis treatment effectiveness

Steroid osteoporosis within the framework of the Itsenko-Cushing drug syndrome: demonstration of a clinical case

Contact Info

Product

Resources

About